Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Captopril
Drug ID BADD_D00354
Description Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment of hypertension.
Indications and Usage For the treatment of essential or renovascular hypertension (usually administered with other drugs, particularly thiazide diuretics). May be used to treat congestive heart failure in combination with other drugs (e.g. cardiac glycosides, diuretics, β-adrenergic blockers). May improve survival in patients with left ventricular dysfunction following myocardial infarction. May be used to treat nephropathy, including diabetic nephropathy.
Marketing Status approved
ATC Code C09AA01
DrugBank ID DB01197
KEGG ID D00251
MeSH ID D002216
PubChem ID 44093
TTD Drug ID D0I0EG
NDC Product Code 27241-162; 31722-141; 31722-142; 0143-1171; 63629-8728; 69292-526; 53296-0031; 31722-144; 0143-1174; 60687-304; 63629-1338; 63629-8730; 0781-8061; 0904-7105; 63629-8729; 70518-3307; 71335-1918; 51552-1072; 51927-0137; 27241-160; 27241-161; 43547-363; 63629-8727; 69292-522; 71335-0826; 0781-8052; 53069-0150; 31722-143; 27241-163; 51407-601; 51407-602; 51407-603; 43547-366; 55289-344; 0781-8080; 55488-0600; 43547-364; 0781-8075; 0143-1172; 0143-1173; 43547-365; 50090-5964; 51407-600; 60687-315; 69292-524; 69292-528; 0904-7106
UNII 9G64RSX1XD
Synonyms Captopril | (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline | Lopirin | SQ-14,534 | SQ 14,534 | SQ14,534 | SQ-14534 | SQ 14534 | SQ14534 | Capoten | SQ-14,225 | SQ 14,225 | SQ14,225 | SQ-14225 | SQ 14225 | SQ14225
Chemical Information
Molecular Formula C9H15NO3S
CAS Registry Number 62571-86-2
SMILES CC(CS)C(=O)N1CCCC1C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Jaundice cholestatic09.01.01.005--Not Available
Laryngeal oedema23.04.01.005; 22.04.02.001; 10.01.05.0030.000732%
Lip swelling23.04.01.007; 10.01.05.005; 07.05.04.0050.000488%Not Available
Loss of consciousness17.02.04.0040.000975%Not Available
Loss of libido19.08.03.003--Not Available
Lung consolidation22.01.02.0100.000488%Not Available
Lymphadenopathy01.09.01.002--Not Available
Malaise08.01.01.003--
Mental impairment19.21.02.003; 17.03.03.0020.000488%Not Available
Microcephaly03.11.02.002; 15.11.02.002--Not Available
Muscular weakness17.05.03.005; 15.05.06.001--
Myalgia15.05.02.001--
Myocardial infarction24.04.04.009; 02.02.02.007--
Nausea07.01.07.001--
Necrosis24.04.02.006; 08.03.03.001--Not Available
Nephritis20.05.02.001--Not Available
Nephrotic syndrome20.05.01.002--
Nervousness19.06.02.003--Not Available
Neutropenia01.02.03.004--Not Available
Oedema08.01.07.006; 14.05.06.0100.000488%Not Available
Oligohydramnios18.05.01.001--Not Available
Oliguria20.01.03.004--Not Available
Orthostatic hypotension24.06.03.004; 17.05.01.020--Not Available
Pain in extremity15.03.04.0100.000488%
Pallor24.03.04.001; 23.03.03.031; 08.01.03.032--Not Available
Palpitations02.11.04.012--
Pancreatitis07.18.01.001--
Pancytopenia01.03.03.003--Not Available
Paraesthesia23.03.03.094; 17.02.06.005--
Patent ductus arteriosus03.07.01.001; 02.08.01.001; 24.03.03.002--Not Available
The 4th Page    First    Pre   4 5 6 7    Next   Last    Total 7 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene